NSC, Sanofi, and A*STAR partner to advance acne treatment research

The collaboration includes a phase 1 clinical study to start in the second quarter of 2025.

The National Skin Centre Singapore, Sanofi, and the Agency for Science, Technology, and Research (A*STAR) have signed a memorandum of understanding (MoU) to advance research in acne treatment.

The collaboration includes a phase 1 clinical study involving patients with mild acne, expected to commence in the second quarter of 2025.

In addition, a translational study will be conducted to explore key biological markers that impact acne severity.

The chronic inflammatory skin condition affects a significant portion of the population, with approximately 80% of teenagers and an increasing number of adults—an estimated 40%—experiencing the condition.

Follow the link s for more news on

healthcare research

partnership

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia